Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254096 | 0.90 | KMT2A (0.40) | KMT2AKDM4EPOLBALDH1A1 | |
| SCHEMBL22617771 | 0.86 | KMT2A (0.39) | KMT2AKDM4E | |
| SCHEMBL10034907 | 0.75 | KMT2A (0.34) | KMT2AKDM4EPOLBALDH1A1 | |
| SCHEMBL20284214 | 0.75 | KDM4E (0.35) | KMT2AKDM4ETSHRPOLB | |
| SCHEMBL16903782 | 0.75 | GRIN2D (0.37) | KMT2AKDM4ETSHR | |
| SCHEMBL16906763 | 0.75 | KMT2A (0.41) | KMT2AKDM4ETSHRALDH1A1 | |
| SCHEMBL15216582 | 0.75 | CYP2D6 (0.37) | KMT2AKDM4ETSHRPOLBALDH1A1 | |
| SCHEMBL19218138 | 0.74 | TSHR (0.36) | KDM4ETSHR | |
| SCHEMBL24955578 | 0.74 | KMT2A (0.31) | KMT2A | |
| SCHEMBL7986537 | 0.73 | KMT2A (0.40) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022130270-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022125989-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2022-06-16 | — | — | WO | disclosed |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| EP-3721943-A1 | LIPIDS, LIPID COMPOSITIONS AND METHODS OF USING THEM | Novartis AG (CH) | 2020-10-14 | — | — | EP | disclosed |
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
| EP-3542789-A2 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN-CODING RNA | GlaxoSmithKline Biologicals SA (BE) | 2019-09-25 | — | — | EP | disclosed |
| EP-2611420-B1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN-CODING RNA | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-03-27 | — | — | EP | disclosed |
| US-9751873-B2 | Aryl sultam derivatives as RORc modulators | GENENTECH, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160168141-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-9301923-B2 | Lipids, lipid compositions, and methods of using them | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-7695728-B2 | 2-substituted pyridines, processes for their preparation and their use for controlling harmful fungi | BASF AKTIENGESELLSCHAFT (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7695728-B2 | 2-substituted pyridines, processes for their preparation and their use for controlling harmful fungi | BASF AKTIENGESELLSCHAFT (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7521396-B2 | Substituted (thioxo)carbonylaminophenyluracils | BAYER CROPSCIENCE AG (DE) | 2009-04-21 | — | — | US | disclosed |
| US-7521396-B2 | Substituted (thioxo)carbonylaminophenyluracils | BAYER CROPSCIENCE AG (DE) | 2009-04-21 | — | — | US | disclosed |
| WO-2008080938-A1 | USE 2-SUBSTITUTED PYRIDINES FOR CANCER TREATMENT | BASF SE (DE) | 2008-07-10 | — | — | WO | disclosed |
| EP-1761516-B1 | 2, 4, 5, 6-SUBSTITUTED PYRIMIDINES, METHOD FOR THE PRODUCTION AND USE THEREOF FOR COMBATING PARASITIC FUNGI | BASF AG (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-20070259919-A1 | 2-Substituted Pyridines, Processes for their Preparation and Their Use for Controlling Harmful Fungi | BASF AKIENGESELLSCHAFT (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259919-A1 | 2-Substituted Pyridines, Processes for their Preparation and Their Use for Controlling Harmful Fungi | BASF AKIENGESELLSCHAFT (DE) | 2007-11-08 | — | — | US | disclosed |
| US-7220765-B2 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) | 2007-05-22 | — | — | US | disclosed |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168141-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | KMT2A 442/4885KDM4E 2105/4885TSHR 178/4885 |
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BCL6, BCL6B, BCOR | KMT2A 216/4885KDM4E 205/4885TSHR 2298/4885 |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SSTR2, SSTR5, SSTR3 | KMT2A 3603/4885KDM4E 4074/4885TSHR 33/4885 |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BCL6, BCL6B, BCOR | KMT2A 229/4885KDM4E 195/4885TSHR 2056/4885 |
| US-20070259919-A1 | 2-Substituted Pyridines, Processes for their Preparation and Their Use for Controlling Harmful Fungi | CYP4X1, CYCS, CYP2S1 | KMT2A 2279/4885KDM4E 1434/4885TSHR 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.